654 related articles for article (PubMed ID: 28906427)
1. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
de Aguiar RB; de Moraes JZ
Front Immunol; 2019; 10():1023. PubMed ID: 31156623
[TBL] [Abstract][Full Text] [Related]
3. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
4. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
Seeber A; Gunsilius E; Gastl G; Pircher A
Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
[TBL] [Abstract][Full Text] [Related]
5. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
Wang N; Jain RK; Batchelor TT
Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
[TBL] [Abstract][Full Text] [Related]
6. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J
Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286
[TBL] [Abstract][Full Text] [Related]
8. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and Glioblastoma: Past, Present, and Future Directions.
Kim MM; Umemura Y; Leung D
Cancer J; 2018; 24(4):180-186. PubMed ID: 30119081
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic Therapy in Colorectal Cancer.
Mody K; Baldeo C; Bekaii-Saab T
Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Choi HJ; Armaiz Pena GN; Pradeep S; Cho MS; Coleman RL; Sood AK
Cancer Metastasis Rev; 2015 Mar; 34(1):19-40. PubMed ID: 25544368
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in advanced lung cancer: state of the art.
Assoun S; Brosseau S; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2515-2535. PubMed ID: 28812378
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in Cervical Cancer: 5 Years After.
Pfaendler KS; Liu MC; Tewari KS
Cancer J; 2018; 24(4):187-192. PubMed ID: 30119082
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and bevacitumab in breast cancer.
Bando H
Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
[TBL] [Abstract][Full Text] [Related]
16. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer.
Markowska A; Sajdak S; Markowska J; Huczyński A
Eur J Med Chem; 2017 Dec; 142():87-94. PubMed ID: 28651817
[TBL] [Abstract][Full Text] [Related]
18. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
19. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
